Foundation Medicine (FMI) Misses Q4 EPS by 9c, Beats on Revenues; Offers FY18 Revenue Outlook Above Consensus

Note: EPS may not be comparable

Foundation Medicine (NASDAQ: FMI) reported Q4 EPS of ($1.05), $0.09 worse than the analyst estimate of ($0.96). Revenue for the quarter came in at $48.9 million versus the consensus estimate of $46.21 million.

GUIDANCE:

Foundation Medicine sees FY2018 revenue of $200-220 million, versus the consensus of $194.82 million.

For earnings history and earnings-related data on Foundation Medicine (FMI) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance